{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:56:13Z","timestamp":1789736173283,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":277,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Achieving a sustained virologic response (SVR) through direct-acting antivirals for hepatitis C virus (HCV) infection significantly reduces the long-term risk of hepatocellular carcinoma (HCC), particularly in patients with advanced fibrosis (F3) or cirrhosis (F4). However, despite this improvement, the risks associated with HCC and the optimal surveillance strategies for patients who have achieved SVR remain topics of debate. This controversy is compounded by challenges in reliably staging liver fibrosis non-invasively, especially at advanced fibrosis (F3), and the unclear cost-effectiveness, modality, frequency, and duration of HCC surveillance in individuals with SVR but without cirrhosis. These factors contribute to significant variations in surveillance guidelines recommended by different professional societies. Therefore, there is a pressing need for an optimal surveillance strategy that is both simplified and cost-effective to facilitate wider adoption by clinicians. This review article evaluates the existing data, addresses ongoing controversies, and aims to provide new perspectives on HCC surveillance strategies for patients who have achieved SVR from HCV.<\/jats:p>","DOI":"10.1093\/gastro\/goae085","type":"journal-article","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T01:42:54Z","timestamp":1724550174000},"source":"Crossref","is-referenced-by-count":9,"title":["New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradication"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-6688","authenticated-orcid":false,"given":"Calvin Q","family":"Pan","sequence":"first","affiliation":[{"name":"Center for Liver Diseases, Guangzhou Medical Research Institute of Infectious Diseases, Guangzhou Eighth People\u2019s Hospital, Guangzhou Medical University , Guangdong, P.R. China"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman School of Medicine , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine, North Shore University Hospital and Donald Barbara Zucker School of Medicine at Hofstra\/Northwell Health , Manhasset, NY, USA"},{"name":"Northwell Center for Liver Disease and Transplantation, Northwell Transplant Institute, Northwell Health , Manhasset, NY, USA"},{"name":"Feinstein Visiting Research Scholar Program, Feinstein Institutes for Medical Research , Manhasset, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-4117","authenticated-orcid":false,"given":"James S","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine, North Shore University Hospital and Donald Barbara Zucker School of Medicine at Hofstra\/Northwell Health , Manhasset, NY, USA"},{"name":"Northwell Center for Liver Disease and Transplantation, Northwell Transplant Institute, Northwell Health , Manhasset, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"Suppl 1","key":"2024092403561002500_goae085-B1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"2024092403561002500_goae085-B2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(95)90400-X","article-title":"HCV-associated liver cancer without cirrhosis","volume":"345","author":"De Mitri","year":"1995","journal-title":"Lancet"},{"key":"2024092403561002500_goae085-B3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/hep.27222","article-title":"Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?","volume":"60","author":"El-Serag","year":"2014","journal-title":"Hepatology"},{"key":"2024092403561002500_goae085-B4","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3748\/wjg.v27.i29.4818","article-title":"New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years","volume":"27","author":"Dennis","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2024092403561002500_goae085-B5","author":"World Health Organization"},{"key":"2024092403561002500_goae085-B6","first-page":"1120","article-title":"Fibrosis regression following hepatitis C antiviral therapy","volume-title":"World J Hepatol","author":"Elsharkawy","year":"2022"},{"key":"2024092403561002500_goae085-B7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis regression after eradication of hepatitis C virus: from bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"key":"2024092403561002500_goae085-B8","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic benefits of HCV cure","volume":"73","author":"Calvaruso","year":"2020","journal-title":"J Hepatol"},{"key":"2024092403561002500_goae085-B9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","article-title":"Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: an ERCHIVES study","volume":"73","author":"Butt","year":"2020","journal-title":"J Hepatol"},{"key":"2024092403561002500_goae085-B10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"2024092403561002500_goae085-B11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"2024092403561002500_goae085-B12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"2024092403561002500_goae085-B13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by DAA reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J Hepatol"},{"key":"2024092403561002500_goae085-B14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"2024092403561002500_goae085-B15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"2024092403561002500_goae085-B16","first-page":"1872","article-title":"Liver fibrosis regression and associated factors in HCV patients treated with direct-acting antiviral agents","volume":"13","author":"Abu-Freha","year":"2023","journal-title":"Life (Basel)"},{"key":"2024092403561002500_goae085-B17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cgh.2013.07.034","article-title":"Liver stiffness is associated with risk of decompensated cirrhosis, hepatocellular carcinoma, and death in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024092403561002500_goae085-B18","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C Guidance 2023 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024092403561002500_goae085-B19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"2024092403561002500_goae085-B20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis patients with HIV\/HCV co-infection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"2024092403561002500_goae085-B21","first-page":"1264","volume":"157","author":"Ioannou"},{"key":"2024092403561002500_goae085-B22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"LokAS. Use of liver imaging and biopsy in clinical practice.","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"key":"2024092403561002500_goae085-B23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/jgh.15243","article-title":"Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: a systematic review and time-to-event meta-analysis.","volume":"36","author":"You","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2024092403561002500_goae085-B24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/hepr.13467","article-title":"Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C.","volume":"50","author":"Ogasawara","year":"2020","journal-title":"Hepatol Res"},{"key":"2024092403561002500_goae085-B25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024092403561002500_goae085-B26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"2024092403561002500_goae085-B27","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"2024092403561002500_goae085-B28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","article-title":"Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma","volume":"42","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"key":"2024092403561002500_goae085-B29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"2024092403561002500_goae085-B30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"2024092403561002500_goae085-B31","first-page":"100578","article-title":"What to do about hepatocellular carcinoma: recommendations for health authorities from the International Liver Cancer Association","volume":"4","author":"Allaire","year":"2022","journal-title":"J Hepathol Rep"},{"key":"2024092403561002500_goae085-B32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","article-title":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol Int"},{"key":"2024092403561002500_goae085-B33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2024092403561002500_goae085-B34","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1365-2036.2004.01963.x","article-title":"Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C","volume":"19","author":"Lin","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2024092403561002500_goae085-B35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1572-0241.2003.07327.x","article-title":"Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis","volume":"98","author":"Arguedas","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2024092403561002500_goae085-B36","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024092403561002500_goae085-B37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000506834","article-title":"A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development","volume":"9","author":"Yoon","year":"2020","journal-title":"Liver Cancer"},{"key":"2024092403561002500_goae085-B38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2021.01.041","article-title":"Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis","volume":"75","author":"Gupta","year":"2021","journal-title":"J Hepatol"},{"key":"2024092403561002500_goae085-B39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"2024092403561002500_goae085-B40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae085\/59275169\/goae085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae085\/59275169\/goae085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T03:56:27Z","timestamp":1727150187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goae085\/7769706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goae085","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2023,12,22]]},"article-number":"goae085"}}